| Keynote Lecture COVID-19 Thursday 13:55-14:40 |
| A-01 Welcome and introduction Thursday 13:00-13:10 |
| A-02 Keynote Lectures COVID-19 Thursday 13:10-14:40 |
| A-03 France Mentré Pharmacometrics to support clinical investigation during COVID-19 pandemics Thursday 13:10-13:55 |
| A-03 Jeremie Guedj Pharmacometrics to support clinical investigation during COVID-19 pandemics : a viral dynamics perspective Thursday 13:10-13:55 |
| A-04 Thorsten Lehr Modeling and Simulation of SARS-CoV-2 Infections, Hospitalizations and Outcome in Germany Thursday 13:55-14:40 |
| A-05 Social break Thursday 14:40-15:40 |
| A-06 PAGE scientific program Thursday 15:40-15:45 |
| A-07 Pharmacometrics to advance management and prevention of COVID-19 Thursday 15:45-16:45 |
| A-08 Nadege Neant Modeling SARS-CoV-2 viral kinetics in hospitalized patients Thursday 15:45-16:05 |
| A-09 Mélanie Prague Using population approach to model COVID-19 epidemics in France: estimating the burden of SARS-Cov-2 and the effects of non-pharmaceutical interventions. Thursday 16:05-16:25 |
| A-10 Seth Robey Predictive Primates: Enabling Rapid Go/No-Go Decisions on COVID-19 Vaccine Candidates with a Predictive, Translational MBMA and Clinical Immunogenicity Data Thursday 16:25-16:45 |
| A-11 Break Thursday 16:45-16:55 |
| A-12 Tutorial Thursday 16:55-17:40 |
| A-13 Andrew Hooker Tutorial on survival analysis and its application to the assessment of competing risks in clinical data analysis. Thursday 16:55-17:10 |
| A-14 Joachim Grevel Tutorial on application of survival analysis to the assessment of multiple state models in clinical data analysis. Thursday 17:10-17:40 |
| A-15 Day End Thursday 17:40 |
| B-01 Poster Session I Friday 12:00-13:00 |
| B-02 Lewis Sheiner Student Session 2020 Friday 13:00-14:20 |
| B-03 Rob van Wijk Translational quantitative systems pharmacology; crossing borders between experimental and computational drug development using zebrafish as model organism Friday 13:00-13:25 |
| B-04 Eleni Karatza Machine-Learning for cancer treatment: Guided covariate selection for TTE models developed from real world data with a small number of patients Friday 13:25-13:50 |
| B-05 Vincent Chang In silico assessment of adaptive trial design for TB regimen development Friday 13:50-14:15 |
| B-06 Presentation Lewis Sheiner Student Session Awards 2020 Friday 14:15-14:20 |
| B-07 Announcement WCOP 2022 Friday 14:20-14:30 |
| B-08 Social Break Friday 14:30-15:30 |
| B-09 Lewis Sheiner Student Session 2021 Friday 15:30-16:45 |
| B-10 Linda Aulin Model-based design of innovative treatment strategies to suppress antimicrobial resistance using collateral sensitivity Friday 15:30-15:55 |
| B-11 Marion Kerioui Bayesian modelling of individual lesions dynamics and survival to characterize response to immunotherapy cancer treatments Friday 15:55-16:20 |
| B-12 Anna Mc Laughlin Population quantitative systems pharmacology model of distinct CAR-T cell phenotypes and CD19-specific metabolic tumour volume reveals sources of high pharmacokinetic variability and overall survival Friday 16:20-16:45 |
| B-13 Presentation Lewis Sheiner Student Session Awards 2021 Friday 16:45-16:50 |
| B-14 Break Friday 16:50-17:00 |
| B-15 Stuart Beal Methodology Session I Friday 17:00-17:40 |
| B-16 Alexander Janssen The Neural Mixed Effects algorithm: leveraging machine learning for pharmacokinetic modelling Friday 17:00-17:20 |
| B-17 James Lu Deep Learning for PK/PD and Disease Progression Time-Course Predictions using Neural-ODE Friday 17:20-17:40 |
| B-18 Day End Friday 17:40 |
| C-01 Poster Session II Monday 12:00-13:00 |
| C-02 Keynote Lecture Monday 13:00-13:45 |
| C-03 Vladimir Dragalin Adaptive trial designs: opportunities and challenges Monday 13:00-13:45 |
| C-04 Break Monday 13:45-13:50 |
| C-05 Oncology-dedicated to Laurent Claret Monday 13:50-15:00 |
| C-06 In Memoriam Laurent Claret Monday 13:50-14:00 |
| C-07 Anyue Yin Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance Monday 14:00-14:20 |
| C-08 Sreenath M Krishnan Multistate model for pharmacometric analyses of overall survival in anticancer treatments Monday 14:20-14:40 |
| C-09 René Bruno Operating characteristics of tumor growth inhibition-overall survival models to support early Phase Ib decisions: An evaluation in first-line metastatic non-small cell lung cancer patients treated with atezolizumab plus chemotherapy based on the Phase III study IMpower150 Monday 14:40-15:00 |
| C-10 Social Break Monday 15:00-16:00 |
| C-11 Integrating machine learning & quantitative pharmacology Monday 16:00-17:00 |
| C-12 Verena Gotta Personalizing hemodialysis (HD) treatment in pediatric patients with end-stage renal disease (ESRD) – application and integration of quantitative pharmacology with machine learning Monday 16:00-16:20 |
| C-13 Jasmine Hughes A hybrid machine learning/pharmacokinetic approach improves predictive performance in model-informed precision dosing Monday 16:20-16:40 |
| C-14 Diego Vera Semi-mechanistic modeling of tumor size and overall survival including machine learning-derived tumor heterogeneity Monday 16:40-17:00 |
| C-15 Break Monday 17:00-17:05 |
| C-16 Improving decision making in drug development and clinical care Monday 17:05-17:45 |
| C-17 Nicolás Marco Ariño The broad use of pharmacometrics in patient care: the case of blood transfusion and perioperative management Monday 17:05-17:25 |
| C-18 Estelle Yau A systematic framework for the incorporation of preclinical species data into physiologically-based pharmacokinetic models using a middle-out approach to improve the translation of drug distribution in humans Monday 17:25-17:45 |
| C-19 Day End Monday 17:45 |
| D-01 Poster Session III Tuesday 12:00-13:00 |
| D-02 Stuart Beal Methodology Session II Tuesday 13:00-14:00 |
| D-03 Carolina Llanos-Paez Use of item-based non-linear mixed effects model to improve confidence in Phase III clinical trial decision-making Tuesday 13:00-13:20 |
| D-04 Iris Minichmayr Beyond disease progression – Item response theory modelling to gain structural insights into disease facets underlying clinical score assessments Tuesday 13:20-13:40 |
| D-05 Alexandra Lavalley-Morelle Individual dynamic predictions in joint analysis for nonlinear marker evolution and competing risk data: application on patients admitted in Intensive Care Unit for sepsis Tuesday 13:40-14:00 |
| D-06 Break Tuesday 14:00-14:20 |
| D-07 Bacterial Diseases Tuesday 14:20-15:30 |
| D-08 In Memoriam Hartmut Derendorf Tuesday 14:20-14:30 |
| D-09 Zoe Kane Development of a neonatal plasma and cerebrospinal fluid (CSF) population PK model for fosfomycin. Tuesday 14:30-14:50 |
| D-10 David Busse Body composition and drug exposure in adipose tissue are key for antibiotic dose-individualisation in obese individuals Tuesday 14:50-15:10 |
| D-11 Jérémy Seurat Combination of in vivo phage therapy data with in silico model highlights key parameters for treatment efficacy Tuesday 15:10-15:30 |
| D-12 Social Break Tuesday 15:30-16:15 |
| D-13 Other infectious & Neurological Diseases Tuesday 16:15-17:15 |
| D-14 Roeland Wasmann A pharmacometric approach to optimise Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide for children with tuberculosis Tuesday 16:15-17:35 |
| D-15 Marie Alexandre Dynamics of the humoral immune response to a two-dose heterologous vaccine regimen against Ebola virus. Tuesday 16:35-16:55 |
| D-16 João Abrantes Model-informed development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties Tuesday 16:55-17:15 |
| D-17 Closing Remarks Tuesday 17:15-17:25 |
| D-18 Audience Input PAGE 2022 Tuesday 17:25-17:40 |
